Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALAWAY vs ACUVUE THERAVISION WITH KETOTIFEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ALAWAY (cetirizine ophthalmic solution) is a selective histamine H1-receptor antagonist that inhibits histamine release from mast cells, reducing ocular itching and allergic conjunctivitis symptoms.
Ketotifen is a selective histamine H1-receptor antagonist and mast cell stabilizer that inhibits the release of inflammatory mediators such as histamine and leukotrienes from mast cells.
Treatment of ocular itching associated with allergic conjunctivitis
FDA-approved for the prevention and treatment of ocular itching associated with allergic conjunctivitis
2 doses (each dose = 2 sprays) per nostril, repeated every 12 hours as needed. Each spray delivers 50 mg of sodium cromoglicate. Route: intranasal. Maximum: 2 doses per nostril per day.
One drop in each affected eye twice daily (approximately 8 hours apart) as needed. The lens should be removed prior to instillation and can be reinserted after at least 10 minutes.
Terminal elimination half-life of 3-4 hours in healthy adults; extended to 10-15 hours in severe renal impairment (Cr Cl <30 m L/min). Clinical context: Twice-daily dosing is standard; dose adjustment required in renal insufficiency.
12 hours (terminal elimination half-life; clinical context: twice-daily dosing needed for continuous effect).
Not extensively metabolized in the eye; systemic metabolism by hepatic CYP450 enzymes is minimal due to low systemic absorption.
Not significantly metabolized in the eye; systemic absorption is minimal. After systemic absorption, it is metabolized primarily via glucuronidation and oxidation, with a half-life of approximately 12 hours.
Primarily renal excretion (80-90% unchanged drug) via glomerular filtration and active tubular secretion; 10-20% fecal excretion. Minimal biliary elimination.
Renal (approximately 50% as unchanged drug, 30% as metabolites); biliary/fecal elimination accounts for <10%.
Approximately 65-75% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein.
99% (primarily albumin and alpha-1-acid glycoprotein).
Vd: 1.0-1.5 L/kg, indicating extensive distribution into total body water and tissues; high penetration into ocular tissues and respiratory mucosa.
2.4 L/kg (high tissue distribution, including ocular tissues).
Oral: ~50% due to first-pass metabolism (CYP3A4 and P-glycoprotein). Ophthalmic solution: negligible systemic absorption (<0.5% of topical dose). Intravenous: 100%.
Ocular topical: ~0.1% systemic; oral: 70% (not relevant for contact lens application).
No dosage adjustment required. Sodium cromoglicate is primarily excreted unchanged in urine, but no specific GFR-based adjustments are recommended due to wide safety margin.
No dosage adjustment required based on renal function; systemic absorption is minimal.
No dosage adjustment required. Sodium cromoglicate is minimally metabolized and undergoes biliary excretion; however, no specific Child-Pugh based modifications are established.
No dosage adjustment required based on hepatic function; systemic absorption is minimal.
Children 2-5 years: 1 spray per nostril every 6-8 hours as needed. Children 6 years and older: same as adult (2 sprays per nostril every 12 hours). Maximum 2 doses per nostril per day in all age groups. Weight-based dosing not established.
Safety and efficacy in pediatric patients below 3 years of age have not been established. For children 3 years and older, administer one drop in each affected eye twice daily.
No specific dose adjustment required; use same adult dose. Caution in elderly with renal impairment due to potential accumulation, though clinical significance is minimal.
No specific dosage adjustment is required for elderly patients; use same dosing as for adults.
None
None
For topical ophthalmic use only,Do not inject,Contact lens wearers should remove lenses before instillation and wait at least 10 minutes before reinserting,May cause temporary blurred vision,Avoid touching dropper tip to any surface to prevent contamination
For topical ophthalmic use only; not for injection.,Contains benzalkonium chloride; soft contact lens wearers should remove lenses before application and wait at least 10 minutes before reinserting.,May cause transient stinging or burning upon instillation.,Use with caution in patients with known hypersensitivity to any component.
Hypersensitivity to cetirizine or any component of the formulation
Hypersensitivity to ketotifen or any component of the product.
No specific food interactions with Alaway ophthalmic solution. Take as directed, regardless of meals. Avoid rubbing eyes after application.
None reported.
ALAWAY (azelastine) is classified as FDA Pregnancy Category C. In animal studies, azelastine administered orally during organogenesis produced fetal malformations (cleft palate, skeletal abnormalities) at maternally toxic doses (≥ 30 mg/kg/day in rats, 68 times the maximum recommended human intranasal dose). There are no adequate and well-controlled studies in pregnant women. First trimester: Risk cannot be ruled out; use only if potential benefit justifies potential risk to fetus. Second and third trimesters: Limited data; avoid use unless necessary due to lack of safety evidence.
Ketotifen ophthalmic solution has minimal systemic absorption (approximately 0.1% of administered dose). No adequate well-controlled studies in pregnant women. Animal studies showed no teratogenicity at doses up to 50 mg/kg/day orally. Risk to fetus is considered low when used topically as directed.
Azelastine is excreted in human breast milk; the milk-to-plasma ratio (M/P) is unknown. In a study of intranasal azelastine (2 sprays per nostril twice daily), the estimated daily infant dose via breast milk is 0.7% of the maternal dose, which is considered low. However, due to the potential for adverse effects in nursing infants (e.g., somnolence, irritability), caution is advised. Use only if clearly needed and benefit outweighs risk. Consider alternative therapies with more safety data.
Ketotifen is excreted in human milk following oral administration; however, systemic absorption from ophthalmic use is negligible. M/P ratio not established for ophthalmic route. Consider benefit vs risk; caution in breastfeeding mothers.
No specific dose adjustments are recommended for pregnancy. However, pharmacokinetic changes during pregnancy (e.g., increased plasma volume, altered hepatic metabolism) may reduce azelastine systemic exposure; the clinical significance is unknown. Use the lowest effective dose for the shortest duration. Maximum recommended intranasal dose: 2 sprays per nostril twice daily (total 548 mcg/day). Avoid exceeding this dose.
No dosage adjustment required. Use as directed; pharmacokinetic changes in pregnancy are not significant for topical ophthalmic route.
Alaway (ketotifen fumarate ophthalmic solution) is used for prevention of itching associated with allergic conjunctivitis. It is a mast cell stabilizer with antihistamine properties. Onset of action occurs within minutes, but may require several days of use for full effect. Advise patients to avoid wearing contact lenses if eyes are red. Remove contacts before instillation and wait at least 10 minutes before reinserting.
Ketotifen is a mast cell stabilizer and antihistamine; contact lens must be removed before instillation and may be reinserted after 10 minutes. Do not use while wearing contact lenses. Advise patient to wait at least 5 minutes between different eye drops. The preservative benzalkonium chloride may be absorbed by soft contact lenses.
Do not touch the dropper tip to any surface to avoid contamination.,Remove contact lenses before using this medication; wait at least 10 minutes after using drops before reinserting.,Use as directed, typically one drop in each affected eye twice daily, with at least 6-8 hours between doses.,Do not use while wearing contact lenses if eyes are red or irritated.,Temporary burning or stinging may occur upon instillation.
Remove contact lenses before using the drops and wait at least 10 minutes before reinserting.,Wash hands before use. Do not touch the dropper tip to any surface, including the eye.,Do not use if the solution changes color or becomes cloudy.,Use exactly as prescribed; do not use more often than directed.,If you miss a dose, use it as soon as possible. If it is almost time for the next dose, skip the missed dose and resume your regular schedule. Do not double the dose.,Contact your doctor if you experience eye pain, vision changes, or if symptoms persist or worsen.
No interactions on record
"Lisdexamfetamine, a prodrug of dextroamphetamine, increases central nervous system (CNS) arousal via dopamine and norepinephrine release, counteracting the sedative effects of ketotifen, a mast cell stabilizer with histamine H1-receptor antagonism and CNS depressant properties. The interaction results in reduced sedative efficacy of ketotifen, potentially affecting therapeutic outcomes in allergic conditions where sedation is beneficial, such as severe pruritus or urticaria. Clinically, patients may experience decreased drowsiness or sleepiness, which could be undesirable if ketotifen is prescribed specifically for its soporific effects."
"Pseudoephedrine, a sympathomimetic amine, exerts central nervous system (CNS) stimulant effects by indirectly activating adrenergic receptors, which can counteract the sedative properties of ketotifen, a histamine H1-receptor antagonist with mast cell stabilizing activity. This pharmacodynamic antagonism may reduce the therapeutic efficacy of ketotifen in managing allergic conditions, particularly its ability to cause drowsiness as a side effect. Clinically, patients may experience diminished sedation, potentially leading to decreased compliance or altered therapeutic outcomes in conditions where sedation is beneficial."
"Hydroxyamphetamine, an indirect-acting sympathomimetic amine, stimulates the release of norepinephrine from presynaptic nerve terminals, leading to activation of alpha- and beta-adrenergic receptors. This produces central nervous system (CNS) stimulation that may oppose the sedative effects of ketotifen, a histamine H1-receptor antagonist with sedative properties. Consequently, coadministration may result in reduced efficacy of ketotifen for sedation or sleep induction, potentially compromising its therapeutic benefit in conditions requiring CNS depression (e.g., allergic rhinitis, urticaria)."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALAWAY vs ACUVUE THERAVISION WITH KETOTIFEN, answered by our medical review team.
ALAWAY is a Ophthalmic Antihistamine that works by ALAWAY (cetirizine ophthalmic solution) is a selective histamine H1-receptor antagonist that inhibits histamine release from mast cells, reducing ocular itching and allergic conjunctivitis symptoms.. ACUVUE THERAVISION WITH KETOTIFEN is a Antihistamine / Mast Cell Stabilizer that works by Ketotifen is a selective histamine H1-receptor antagonist and mast cell stabilizer that inhibits the release of inflammatory mediators such as histamine and leukotrienes from mast cells.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALAWAY and ACUVUE THERAVISION WITH KETOTIFEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALAWAY is: 2 doses (each dose = 2 sprays) per nostril, repeated every 12 hours as needed. Each spray delivers 50 mg of sodium cromoglicate. Route: intranasal. Maximum: 2 doses per nostril per day.. The standard adult dose of ACUVUE THERAVISION WITH KETOTIFEN is: One drop in each affected eye twice daily (approximately 8 hours apart) as needed. The lens should be removed prior to instillation and can be reinserted after at least 10 minutes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALAWAY and ACUVUE THERAVISION WITH KETOTIFEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALAWAY is classified as Category C. ALAWAY (azelastine) is classified as FDA Pregnancy Category C. In animal studies, azelastine administered orally during organogenesis produced fetal malformations (cleft palate, sk. ACUVUE THERAVISION WITH KETOTIFEN is classified as Category A/B. Ketotifen ophthalmic solution has minimal systemic absorption (approximately 0.1% of administered dose). No adequate well-controlled studies in pregnant women. Animal studies showe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.